Sputum periostin in patients with different severe asthma phenotypes

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 70, Issue 5, 2015, Pages 540-546

  Bobolea, Irina ^a   Barranco, P ^b,c   Del Pozo, V ^c,d   Romero, D ^b   Sanz, V ^c,d   Lopez Carrasco V ^b   Canabal, J ^b   Villasante, C ^b   Quirce, S ^b,c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UAM)   (Spain)

Author keywords

asthma biomarkers; asthma phenotypes; induced sputum; periostin; severe asthma

Indexed keywords

IMMUNOGLOBULIN E; NITRIC OXIDE; TRANSCRIPTION FACTOR RUNX2; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; ASTHMA; CONTROLLED STUDY; EOSINOPHIL COUNT; EXPIRED AIR; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMATIMETRY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPHENOTYPING; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MOLECULAR PATHOLOGY; OBSERVATIONAL STUDY; PRICK TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEVERE ASTHMA; SKIN TEST; SPIROMETRY; SPUTUM; SUPERNATANT; TH2 CELL; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MIDDLE AGED; PHENOTYPE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ASTHMA; BIOMARKERS; CELL ADHESION MOLECULES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; RESPIRATORY FUNCTION TESTS; SKIN TESTS; SPUTUM; YOUNG ADULT;

EID: 84926406796     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12580     Document Type: Article

References (29)

1. Wenzel SE, Busse WW,; National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Severe asthma: lessons from the Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119: 14-21.
2. Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, et al. National Heart, Lung, Blood Institute's Severe Asthma Research Program. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol 2007; 119: 405-413.
3. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, et al. Unbiased Biomarkers for the Prediction of Respiratory Disease Outcome (U-BIOPRED) Consortium, Consensus Generation. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax 2011; 66: 910-917.
4. Pavord ID, Wardlaw AJ,. The A to E of airway disease. Clin Exp Allergy 2010; 40: 62-67.
5. Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE,. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004; 113: 101-108.
6. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360: 1715-1721.
7. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984.
8. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388-395. Erratum, Am J Respir Crit Care Med 2009; 180: 796.
9. Corren J, Lemanske RF Jr, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088-1098.
10. Takeshita S, Kikuno R, Tezuka K, Amann E,. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 1993; 294 (Pt 1): 271-278.
11. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, et al. Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012; 130: 647-654.
12. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000; 162: 2341-2351.
13. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European network for understanding mechanisms of severe asthma. Eur Respir J 2003; 22: 470-477.
14. Dreborg S, Frew AJ,. EAACI Position paper: allergen standardization and skin tests. The European academy of allergology and clinical immunology. Allergy 1993; 48: 48-82.
15. American Thoracic Society. Standardization of spirometry- 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136.
16. Bel EH, ten Brinke A, Sorkness RL,. Fixed airway obstruction in severe asthma. Eur Respir Mon 2011; 51: 147-159.
17. Lee JH, Haselkorn T, Borish L, Rasouliyan L, Chipps BE, Wenzel SE,. Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma: insights from the TENOR study. Chest 2007; 132: 1882-1889.
18. Menzies D, Nair A, Lipworth BJ,. Portable nitric oxide measurement. Comparison with the "gold standard'' technique. Chest 2007; 131: 410-414.
19. Efthimiadis A, Spanevello A, Hamid Q, Kelly MM, Linden M, Louis R, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J 2002; 20 (suppl 37): S19-S23.
20. Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, et al. National Heart, Lung, and Blood Institute Severe Asthma Research Program. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 2010; 125: 1028-1036.
21. Gibson PG, Wang F, He XY, Brightling CE,. Noninvasive assessment of inflammation in severe asthma. Eur Resp Mon 2011; 51: 208-217.
22. Simpson JL, Word LG, Gibson PG,. Inflammatory mediators in exhaled breath, induced sputum and saliva. Clin Exp Allergy 2005; 35: 1180-1185.
23. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. American Thoracic Society/European Respiratory Society Task Force on Asthma Control and Exacerbations. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.
24. Wenzel SE,. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716-725.
25. Parulekar AD, Atik MA, Hanania NA,. Periostin, a novel biomarker of Th2-driven asthma. Curr Opin Pulm Med 2014; 20: 60-65.
26. Kanemitsu Y, Matsumoto H, Izuhara K, Tohda Y, Kita H, Horiguchi T, et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013; 132: 305-312.
27. Pepe C, Foley S, Shannon J, Lemiere C, Olivenstein R, Ernst P, et al. Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol 2005; 116: 544-549.
28. Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodruff PG, Fahy JV,. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol 2014; 133: 388-394.
29. Sterk PJ, Lutter R,. Asthma phenotyping: TH2-high, TH2-low, and beyond. J Allergy Clin Immunol 2014; 133: 395-396.